Table 1. Sources of valid T, N, and M components: completeness of variables and contribution to final staging.
|
Data sets |
Colorectal |
Lung |
||||
|---|---|---|---|---|---|---|
| Variables | Audit | CAS | Completeness count (%) | Contribution count (%) | Completeness count (%) | Contribution count (%) |
|
T component | ||||||
| pT | • | 32 648 (19.9) | 32 017 (19.5)a | 15 427 (9.2) | 15 427 (9.2) | |
| Serosal involvement or perforation | • | 5209 (3.2) | 710 (0.4) | NA | NA | |
| pT | • | 77 997 (47.6) | 52 761 (32.2) | 14 933 (8.9) | 5970 (3.6) | |
| cT | • | 48 204 (29.4) | 16 113 (9.8) | 107 171 (63.7) | 89 265 (53.1) | |
| Result from MRI | • | 22 056 (13.5) | 2295 (1.4) | NA | NA | |
| cT | • | 5773 (3.5) | 754 (0.5) | 7952 (4.7) | 1217 (0.7) | |
| iT | • | 104 047 (63.5) | 11 358 (6.9) | 91 917 (54.7) | 11 437 (6.8) | |
| Missing T component | 47 907 (29.2) | 44 842 (26.7) | ||||
|
N component | ||||||
| pN | • | 32 666 (19.9) | 32 518 (19.8)a | 15 177 (9.0) | 15 177 (9.0) | |
| Count of positive lymph nodes | • | 14 523 (8.9) | 310 (0.2) | NA | NA | |
| pN | • | 74 212 (45.3) | 49 351 (30.1) | 15 180 (9.0) | 6914 (4.1) | |
| Count of positive lymph nodes | • | 35 695 (21.8) | 4656 (2.8) | 3511 (2.1) | 841 (0.5) | |
| cN | • | 50 108 (30.6) | 16 141 (9.9) | 107 300 (63.8) | 88 336 (52.5) | |
| Result from MRI | • | 20 387 (12.4) | 1319 (0.8) | NA | NA | |
| cN | • | 6576 (4.0) | 1261 (0.8) | 8085 (4.8) | 1274 (0.8) | |
| iN | • | 101 453 (61.9) | 9574 (5.8) | 91 693 (54.5) | 11 349 (6.7) | |
| Missing N component | 48 785 (29.8) | 44 267 (26.3) | ||||
|
M component | ||||||
| cM | • | 51 542 (31.4) | 50 548 (30.8)a | 107 057 (63.7) | 107 057 (63.7) | |
| Distant metastasis | • | 17 890 (10.9) | 8727 (5.3) | NA | NA | |
| Result from liver CT | • | 75 714 (46.2) | 1064 (0.6) | NA | NA | |
| cM | • | 13 212 (8.1) | 6548 (4.0) | 8987 (5.3) | 1894 (1.1) | |
| pM | • | 10 333 (6.3) | 3248 (2.0) | 10 845 (6.4) | 648 (0.4) | |
| pM | • | 10 936 (6.7) | 4170 (2.5) | 9675 (5.8) | 2944 (1.8) | |
| iM | • | 67 948 (41.5) | 18 800 (11.5) | 92 930 (55.3) | 14 197 (8.4) | |
| Clinical examination | 3294 (2.0) | 3056 (1.8) | ||||
| Missing M component | 67 516 (41.2) | 38 362 (22.8) | ||||
|
Summary stageb | ||||||
| pStage | • | 30 239 (18.4)c | 2206 (1.3)c | 16 946 (10.1) | 20 (<0.01) | |
| cStage | • | 80 036 (48.8)c | 1098 (0.7)c | 105 410 (62.7) | 485 (0.3) | |
| pStage | • | 4351 (2.7) | 38 (<0.01) | 2117 (1.3) | 41 (<0.01) | |
| cStage | • | 508 (0.3) | 5 (<0.01) | 679 (0.4) | 7 (<0.01) | |
| iStage | • | 57 596 (35.1) | 1189 (0.7) | 85 267 (50.7) | 1520 (0.9) | |
| Stage | • | 108 105 (66.0)d | 4003 (2.4)d | NA | NA | |
| Total | 163 915 | 168 158 | ||||
Abbreviations: CAS=Cancer Analysis System; M=metastases; MRI=magnetic resonance imaging; N=lymph nodes; NA=not available; T=tumour. Colorectal and lung cancer diagnoses in England, 2008–2012. Prefixes: p: pathological; c: clinical; i: integrated (origin may be pathological, clinical, highest value, or simply flagged by the registry).
a
Some zero values for this variable are replaced by positive values in the next step of the algorithm, where the contribution to final staging is made. Therefore, completeness of this variable does not equal its contribution to final staging.
b
Summary stage variables contribute to non-restrictive strategy only.
c
Dukes stage from Audit.
d
Dukes stage from CAS.